Why the study?
Venous thromboembolism management is complex in patients with cancer due to increased recurrence and major bleeding risks during anticoagulation, requiring updated guidance based on recent evidence.
The 2024 Spanish Society of Internal Medicine (SEMI) guidelines provide updated, evidence-based recommendations for the complex management of venous thromboembolism in patients with cancer.
Informs current VTE management in cancer patients; extends recent evidence into updated national guidelines.
Vennous thromboembolism (VTE) is a common complication associated to greater mortality in patients with cancer. Its etiology is multifactorial and depends on the characteristics and co-morbidities of the patient, the tumor type and extension, and the oncological treatment. The management of VTE is more complex in patients with cancer due to an increased risk of recurrence and major bleeding complications during anticoagulation compared to the general non-oncological population. The above differences have led to the development of specific clinical trials to assess the efficacy and safety of anticoagulant therapy in patients with cancer. The present clinical guidelines are intended to provide general recommendations on the management of cancer-associated VTE according to updated according to the most recent scientific evidence.
No takes yet. Share an insight, caveat, or question.
Villalobos et al. (2024) conducted a review in Cancer-associated venous thromboembolism. Anticoagulant therapy was evaluated. The 2024 Spanish Society of Internal Medicine guidelines provide updated recommendations for the management of cancer-associated venous thromboembolism based on recent scientific evidence.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: